ABIVAX

  • ISIN: FR0012333284
  • Land: Frankreich

Nachricht vom 07.06.2021 | 18:00

Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

DGAP-News: ABIVAX / Key word(s): AGM/EGM
07.06.2021 / 18:00
The issuer is solely responsible for the content of this announcement.

Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

Shareholders approved all proposed resolutions

PARIS, France, June 7, 2021 - 6:00 pm (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, held its ordinary annual and extraordinary general meeting of shareholders on June 4, 2021, which was chaired by Philippe Pouletty, Chairman of the Board of directors, without the physical presence of the shareholders.

The shareholders have adopted all the resolutions approved by the Board of Directors and, in particular, the financial statements for the 2020 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board of Directors related to financial transactions.

Shareholders also approved the reappointments of Philippe Pouletty, Truffle Capital, Santé Holding SRL and Corinna Zur Bonsen-Thomas as Board members.

Details on the vote results will be available on the company's website.

About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
 
Investors
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254
 
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
 
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
Public Relations France
DGM Conseil
Thomas Roborel de Climens
thomasdeclimens@dgm-conseil.fr
+33 6 14 50 15 84
Public Relations USA
Rooney Partners LLC
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017


07.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

IPO im Fokus

MIT SICHERHEIT AUFS PARKETT. UNSER BÖRSENGANG ZUR WACHSTUMSBESCHLEUNIGUNG

ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

IIF – International Investment Forum

Wann: 14. Oktober 2021, 9:45 - 18:00 Uhr
Wo: Online Live-Event via ZOOM
Wer: börsennotierte Unternehmen aus den Small- und Midcap-Segmenten aller Welt
Branchen: Technologie, Rohstoffe, Sicherheit, Medizin, Logistik und Raumfahrt
Für: Alle Investoren & Presse
Weitere Informationen: www.ii-forum.com

Aktuelle Research-Studie

2G Energy AG

Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Hinzufügen

15. Oktober 2021